Cargando…
Efficacy and safety of intravenous iron repletion in patients with heart failure: a systematic review and meta-analysis
INTRODUCTION: AFFIRM-AHF and IRONMAN demonstrated lower rates of the combined endpoint recurrent heart failure (HF) hospitalizations and cardiovascular death (CVD) using intravenous (IV) ferric carboxymaltose (FCM) and ferric derisomaltose (FDI), respectively in patients with HF and iron deficiency...
Autores principales: | Vukadinović, Davor, Abdin, Amr, Emrich, Insa, Schulze, P. Christian, von Haehling, Stephan, Böhm, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116902/ https://www.ncbi.nlm.nih.gov/pubmed/37074386 http://dx.doi.org/10.1007/s00392-023-02207-2 |
Ejemplares similares
-
Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials
por: Abdin, Amr, et al.
Publicado: (2022) -
Iron Deficiency in Heart Failure: A Practical Guide
por: Ebner, Nicole, et al.
Publicado: (2013) -
Iron deficiency in heart failure
por: Loncar, Goran, et al.
Publicado: (2021) -
Why is Iron Deficiency Recognised as an Important Comorbidity in Heart Failure?
por: Ebner, Nicole, et al.
Publicado: (2019) -
Impact of the COVID-19 pandemic on implementation of novel guideline-directed medical therapies for heart failure in Germany: a nationwide retrospective analysis
por: Kerwagen, Fabian, et al.
Publicado: (2023)